AlzChem Group (ACT) Q3 2025 earnings summary

Executive summary

• Specialty Chemicals segment drove growth, with sales up 9% and EBITDA up 16% year-over-year, offsetting declines in other segments.

• Q3 sales increased 6–6.5% year-over-year, and nine-month sales rose 2–2.3% to €424.8 million.

• EBITDA for nine months rose 12–12.2% to €86.2 million, with margin improving from 18.5% to 20.3%.

• New creatine facility commissioned and capacity expanded, with strategic partnership with Ehrmann launching creatine-based products in supermarkets.

• Outlook for 2025 confirmed, expecting record sales and EBITDA.

Financial highlights

• Q3 2025 revenue: €137.3 million (+6.5% YoY); 9M 2025 revenue: €424.8 million (+2.3% YoY).

• Q3 2025 EBITDA: €29.7 million (+19.5% YoY); 9M 2025 EBITDA: €86.2 million (+12.2% YoY); margin at 20.3%.

• Net income for nine months rose 20% to €46.8 million; EPS up to €4.62.

• Operating cash flow for nine months increased to €115.5 million (+53.8% YoY).

• Free cash flow remained strong at €48.1 million despite record capital expenditure.

Outlook and guidance

• 2025 sales forecast: approximately €580 million; EBITDA forecast: at least €113–130 million.

• Growth expected mainly from Specialty Chemicals, especially Creapure®, Creamino®, and Nitroguanidin.

• Basics & Intermediates segment expected to see slight sales decline due to steel industry weakness.

• No material negative impact expected from US tariffs; further US dollar weakening could affect results.

• Inventory intensity and equity ratio expected to remain stable.